

# Derek J Rosario

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6743457/publications.pdf>

Version: 2024-02-01

130  
papers

9,373  
citations

100601

38  
h-index

45040

94  
g-index

140  
all docs

140  
docs citations

140  
times ranked

11588  
citing authors

#	ARTICLE	IF	CITATIONS
1	Functional and quality of life outcomes of localised prostate cancer treatments (Prostate Testing) Tj ETQq1 1 0.784314 rgBT /Overlo	1.3	23
2	Urethral recurrence after radical cystoprostatectomy: Experience from a high-volume tertiary referral centre. <i>Journal of Clinical Urology</i> , 2021, 14, 238-245.	0.1	1
3	False Positive Multiparametric Magnetic Resonance Imaging Phenotypes in the Biopsy-naïve Prostate: Are They Distinct from Significant Cancer-associated Lesions? Lessons from PROMIS. <i>European Urology</i> , 2021, 79, 20-29.	0.9	13
4	The development of a theory and evidence-based intervention to aid implementation of exercise into the prostate cancer care pathway with a focus on healthcare professional behaviour, the STAMINA trial. <i>BMC Health Services Research</i> , 2021, 21, 273.	0.9	8
5	Towards implementing exercise into the prostate cancer care pathway: development of a theory and evidence-based intervention to train community-based exercise professionals to support change in patient exercise behaviour (The STAMINA trial). <i>BMC Health Services Research</i> , 2021, 21, 264.	0.9	6
6	Remote interventions to improve exercise behaviour in sedentary people living with and beyond cancer: a systematic review and meta-analysis. <i>BMC Cancer</i> , 2021, 21, 308.	1.1	14
7	Embedding supervised exercise training for men on androgen deprivation therapy into standard prostate cancer care: a feasibility and acceptability study (the STAMINA trial). <i>Scientific Reports</i> , 2021, 11, 12470.	1.6	3
8	Cardiovascular Disease and the Androgen Receptor: Here We Go Again?. <i>European Urology</i> , 2020, 77, 167-169.	0.9	1
9	Prescription switching: Rationales and risks. <i>International Journal of Clinical Practice</i> , 2020, 74, e13429.	0.8	4
10	The ProtecT trial: analysis of the patient cohort, baseline risk stratification and disease progression. <i>BJU International</i> , 2020, 125, 506-514.	1.3	32
11	Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received. <i>European Urology</i> , 2020, 77, 320-330.	0.9	107
12	The ProtecT randomised trial cost-effectiveness analysis comparing active monitoring, surgery, or radiotherapy for prostate cancer. <i>British Journal of Cancer</i> , 2020, 123, 1063-1070.	2.9	15
13	A critical evaluation of visual proportion of Gleason 4 and maximum cancer core length quantified by histopathologists. <i>Scientific Reports</i> , 2020, 10, 17177.	1.6	4
14	Strategies adopted by men to deal with uncertainty and anxiety when following an active surveillance/monitoring protocol for localised prostate cancer and implications for care: a longitudinal qualitative study embedded within the ProtecT trial. <i>BMJ Open</i> , 2020, 10, e036024.	0.8	7
15	What Type of Prostate Cancer Is Systematically Overlooked by Multiparametric Magnetic Resonance Imaging? An Analysis from the PROMIS Cohort. <i>European Urology</i> , 2020, 78, 163-170.	0.9	60
16	The Impact of Centralised Services on Metric Reflecting High-quality Performance: Outcomes from 1110 Consecutive Radical Cystectomies at a Single Centre. <i>European Urology Focus</i> , 2020, 7, 554-565.	1.6	7
17	Additional Value of Dynamic Contrast-enhanced Sequences in Multiparametric Prostate Magnetic Resonance Imaging: Data from the PROMIS Study. <i>European Urology</i> , 2020, 78, 503-511.	0.9	27
18	Comparison of Transrectal Ultrasound Biopsy to Transperineal Template Mapping Biopsies Stratified by Multiparametric Magnetic Resonance Imaging Score in the PROMIS Trial. <i>Journal of Urology</i> , 2020, 203, 100-107.	0.2	9

#	ARTICLE	IF	CITATIONS
19	Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT. <i>Health Technology Assessment</i> , 2020, 24, 1-176.	1.3	22
20	Psychosocial impact of undergoing prostate cancer screening for men with <i><sc>BRCA</sc>1 or <sc>BRCA</sc>2</i> mutations. <i>BJU International</i> , 2019, 123, 284-292.	1.3	9
21	Factors associated with trial recruitment, preferences, and treatments received were elucidated in a comprehensive cohort study. <i>Journal of Clinical Epidemiology</i> , 2019, 113, 200-213.	2.4	6
22	Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. <i>European Urology</i> , 2019, 76, 831-842.	0.9	148
23	In-bore Multiparametric Magnetic Resonance Imaging Targeted Biopsy: As Good as it Gets?. <i>European Urology</i> , 2019, 75, 579-581.	0.9	4
24	Long-term Outcomes from Re-resection for High-risk Non-muscle-invasive Bladder Cancer: A Potential to Rationalize Use. <i>European Urology Focus</i> , 2019, 5, 650-657.	1.6	38
25	Islam and the Urinary Stoma: A Contemporary Theological and Urological Dilemma. <i>European Urology Focus</i> , 2019, 5, 301-305.	1.6	7
26	A prospective cohort and extended comprehensive-cohort design provided insights about the generalizability of a pragmatic trial: the ProtecT prostate cancer trial. <i>Journal of Clinical Epidemiology</i> , 2018, 96, 35-46.	2.4	16
27	Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. <i>British Journal of Cancer</i> , 2018, 118, 266-276.	2.9	12
28	Interventions for promoting habitual exercise in people living with and beyond cancer. <i>The Cochrane Library</i> , 2018, 2018, CD010192.	1.5	126
29	Exercise training as a novel primary treatment for localised prostate cancer: a multi-site randomised controlled phase II study. <i>Scientific Reports</i> , 2018, 8, 8374.	1.6	24
30	A multi-centre investigation of delivering national guidelines on exercise training for men with advanced prostate cancer undergoing androgen deprivation therapy in the UK NHS. <i>PLoS ONE</i> , 2018, 13, e0197606.	1.1	19
31	Treatment in the STAMPEDE era for castrate resistant prostate cancer in the UK: ongoing challenges and underappreciated clinical problems. <i>BMC Cancer</i> , 2018, 18, 667.	1.1	4
32	Supportive interventions to improve physiological and psychological health outcomes among patients undergoing cystectomy: a systematic review. <i>BMC Urology</i> , 2018, 18, 71.	0.6	8
33	Overcoming difficulties with equipoise to enable recruitment to a randomised controlled trial of partial ablation vs radical prostatectomy for unilateral localised prostate cancer. <i>BJU International</i> , 2018, 122, 970-977.	1.3	17
34	Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study. <i>Health Technology Assessment</i> , 2018, 22, 1-176.	1.3	70
35	Partial ablation versus radical prostatectomy in intermediate-risk prostate cancer: the PART feasibility RCT. <i>Health Technology Assessment</i> , 2018, 22, 1-96.	1.3	33
36	Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial. <i>Lancet Oncology</i> , 2017, 18, 181-191.	5.1	263

#	ARTICLE	IF	CITATIONS
37	PD56-08 THE PART TRIAL - A PHASE III STUDY COMPARING PARTIAL PROSTATE ABLATION VERSUS RADICAL PROSTATECTOMY (PART) IN INTERMEDIATE RISK PROSTATE CANCER – EARLY DATA FROM THE FEASIBILITY STUDY. <i>Journal of Urology</i> , 2017, 197, .	0.2	3
38	Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial. <i>European Urology</i> , 2017, 71, 381-388.	0.9	41
39	Managing cardiovascular risk in high-risk prostate cancer. <i>Trends in Urology &amp; Men's Health</i> , 2017, 8, 13-18.	0.2	1
40	Evaluation of a short RNA within Prostate Cancer Gene 3 in the predictive role for future cancer using non-malignant prostate biopsies. <i>PLoS ONE</i> , 2017, 12, e0175070.	1.1	2
41	The modern role of androgen deprivation therapy in the management of localised and locally advanced prostate cancer. <i>Journal of Clinical Urology</i> , 2016, 9, 24-29.	0.1	18
42	The role of gonadotrophin-releasing hormone antagonists in the treatment of patients with advanced hormone-dependent prostate cancer in the UK. <i>World Journal of Urology</i> , 2016, 34, 1601-1609.	1.2	37
43	Castration-resistant Prostate Cancer: Preservation of Quality of Life and Well-being. <i>European Urology Focus</i> , 2016, 2, 472-475.	1.6	1
44	Radiotherapy for Prostate Cancer: is it “what you do” or “the way that you do it”? A UK Perspective on Technique and Quality Assurance. <i>Clinical Oncology</i> , 2016, 28, e92-e100.	0.6	7
45	10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 1415-1424.	13.9	2,101
46	Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 1425-1437.	13.9	962
47	Effects of a lifestyle intervention on endothelial function in men on long-term androgen deprivation therapy for prostate cancer. <i>British Journal of Cancer</i> , 2016, 114, 401-408.	2.9	48
48	Exercise for Men with Prostate Cancer: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2016, 69, 693-703.	0.9	207
49	The clinical need for undergraduate urology. <i>Clinical Teacher</i> , 2015, 12, 353-355.	0.4	9
50	A profile of enzalutamide for the treatment of advanced castration resistant prostate cancer. <i>Cancer Management and Research</i> , 2015, 7, 153.	0.9	7
51	Survivorship and Improving Quality of Life in Men with Prostate Cancer. <i>European Urology</i> , 2015, 68, 374-383.	0.9	91
52	Mortality Following Radical Cystectomy: A Good Start, but How Low Can We Go?. <i>European Urology</i> , 2015, 67, 1063-1065.	0.9	3
53	Role of information in preparing men for transrectal ultrasound guided prostate biopsy: a qualitative study embedded in the ProtecT trial. <i>BMC Health Services Research</i> , 2015, 15, 80.	0.9	16
54	Adverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate Them. <i>European Urology</i> , 2015, 67, 825-836.	0.9	561

#	ARTICLE	IF	CITATIONS
55	Progress Toward Embracing Exercise Training As an Integral Part of Prostate Cancer Treatment. <i>Journal of Clinical Oncology</i> , 2014, 32, 2517-2518.	0.8	1
56	Response to comment on "Interventions to improve exercise behaviour in sedentary people living with and beyond cancer: a systematic review". <i>British Journal of Cancer</i> , 2014, 111, 2378-2379.	2.9	1
57	Lifestyle Changes for Improving Disease-specific Quality of Life in Sedentary Men on Long-term Androgen-Deprivation Therapy for Advanced Prostate Cancer: A Randomised Controlled Trial. <i>European Urology</i> , 2014, 65, 865-872.	0.9	164
58	Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study. <i>European Urology</i> , 2014, 66, 489-499.	0.9	195
59	Interventions to improve exercise behaviour in sedentary people living with and beyond cancer: a systematic review. <i>British Journal of Cancer</i> , 2014, 110, 831-841.	2.9	103
60	Androgen Deprivation Therapy and Cardiovascular Harm: Are All Men Created Equal?. <i>European Urology</i> , 2014, 65, 574-576.	0.9	6
61	Systematic Review of Complications of Prostate Biopsy. <i>European Urology</i> , 2013, 64, 876-892.	0.9	779
62	1295 SNAPSHOT OF TRANSURETHRAL RESECTION OF NEW BLADDER TUMOURS IN THE UK AUDIT (STUKA). <i>Journal of Urology</i> , 2013, 189, .	0.2	0
63	Interventions for promoting habitual exercise in people living with and beyond cancer. <i>The Cochrane Library</i> , 2013, , CD010192.	1.5	136
64	Haematuria. <i>Surgery</i> , 2013, 31, 509-515.	0.1	1
65	Disease Specific Mortality in Patients with Low Risk Bladder Cancer and the Impact of Cystoscopic Surveillance. <i>Journal of Urology</i> , 2013, 189, 828-833.	0.2	50
66	Transurethral resection biopsy as part of a saturation biopsy protocol: A cohort study and review of the literature. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 542-548.	0.8	3
67	Competing mortality in patients diagnosed with bladder cancer: evidence of undertreatment in the elderly and female patients. <i>British Journal of Cancer</i> , 2013, 108, 1534-1540.	2.9	153
68	Endocrine therapy in prostate cancer: time for reappraisal of risks, benefits and cost-effectiveness?. <i>British Journal of Cancer</i> , 2013, 108, 9-13.	2.9	52
69	Psychological Impact of Prostate Biopsy: Physical Symptoms, Anxiety, and Depression. <i>Journal of Clinical Oncology</i> , 2013, 31, 4235-4241.	0.8	81
70	Assessment of endothelial dysfunction by flow-mediated dilatation in men on long-term androgen deprivation therapy for prostate cancer. <i>Experimental Physiology</i> , 2013, 98, 1401-1410.	0.9	18
71	Republished editorial: Physical activity for cancer survivors: Beneficial in the short term, but longer term outcomes are lacking. <i>British Journal of Sports Medicine</i> , 2013, 47, 568-568.	3.1	1
72	Reply: Endocrine therapy in prostate cancer: time for reappraisal of risks, benefits and cost-effectiveness?. <i>British Journal of Cancer</i> , 2013, 108, 2194-2194.	2.9	4

#	ARTICLE	IF	CITATIONS
73	Snapshot of transurethral resection of bladder tumours in the United Kingdom Audit (STUKA). BJU International, 2013, 112, 930-935.	1.3	16
74	SABRE 1 (Surgery Against Brachytherapy - a Randomised Evaluation): feasibility randomised controlled trial (RCT) of brachytherapy vs radical prostatectomy in low-intermediate risk clinically localised prostate cancer. BJU International, 2013, 112, 330-337.	1.3	18
75	Nuclear targeting of dystroglycan promotes the expression of androgen regulated transcription factors in prostate cancer. Scientific Reports, 2013, 3, 2792.	1.6	30
76	Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study. BMJ: British Medical Journal, 2012, 344, d7894-d7894.	2.4	211
77	An evaluation of urinary microRNA reveals a high sensitivity for bladder cancer. British Journal of Cancer, 2012, 107, 123-128.	2.9	135
78	Cardiovascular risk in androgen suppression: underappreciated, under-researched and unresolved: Figure 1. Heart, 2012, 98, 345-348.	1.2	10
79	Physical activity for cancer survivors. BMJ: British Medical Journal, 2012, 344, d7998-d7998.	2.4	8
80	A qualitative study evaluating experiences of a lifestyle intervention in men with prostate cancer undergoing androgen suppression therapy. Trials, 2012, 13, 208.	0.7	41
81	The long-term outcome of treated high-risk nonmuscle-invasive bladder cancer. Cancer, 2012, 118, 5525-5534.	2.0	38
82	183 URINARY MICRORNA IN BLADDER CANCER - A POTENTIAL DIAGNOSTIC TOOL. European Urology Supplements, 2011, 10, 81.	0.1	1
83	A novel cost-effective approach to post-vasectomy semen analysis. BJU International, 2011, 107, 1447-1452.	1.3	8
84	Weight Loss and Exercise in Obese Older Adults. New England Journal of Medicine, 2011, 364, 2466-2468.	13.9	1
85	Lifestyle Intervention in Men with Advanced Prostate Cancer Receiving Androgen Suppression Therapy: A Feasibility Study. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 647-657.	1.1	136
86	Suitability of PSA-detected localised prostate cancers for focal therapy: experience from the ProtecT study. British Journal of Cancer, 2011, 105, 931-937.	2.9	18
87	The Application of Artificial Intelligence to Microarray Data: Identification of a Novel Gene Signature to Identify Bladder Cancer Progression. European Urology, 2010, 57, 398-406.	0.9	52
88	In Vitro Release of Adenosine Triphosphate from the Urothelium of Human Bladders with Detrusor Overactivity, Both Neurogenic and Idiopathic. European Urology, 2010, 57, 1087-1092.	0.9	72
89	A phase I trial of intra-lymph-node administration of a novel immunotherapeutic regimen (MKC1106-MT) in patients with advanced melanoma.. Journal of Clinical Oncology, 2010, 28, 8535-8535.	0.8	0
90	Neurofuzzy Modeling to Determine Recurrence Risk Following Radical Cystectomy for Nonmetastatic Urothelial Carcinoma of the Bladder. Clinical Cancer Research, 2009, 15, 3150-3155.	3.2	24

#	ARTICLE	IF	CITATIONS
91	Distinct MicroRNA Alterations Characterize High- and Low-Grade Bladder Cancer. <i>Cancer Research</i> , 2009, 69, 8472-8481.	0.4	291
92	Re: Rosario DJ, Woo HH, Chapple CR. 2008. Definition of normality of pressure-flow parameters based on observations in asymptomatic men. <i>Neurourol and Urodynam</i> 27:388-394. <i>Neurourology and Urodynamics</i> , 2009, 28, 364-364.	0.8	0
93	Re: Rosario DJ, Woo HH, Chapple CR. 2008. Definition of normality of pressure-flow parameters based on observations in asymptomatic men. <i>Neurourol and Urodynam</i> 27:388-394. <i>Neurourology and Urodynamics</i> , 2009, 28, 363-363.	0.8	1
94	Definition of normality of pressure-flow parameters based on observations in asymptomatic men. <i>Neurourology and Urodynamics</i> , 2008, 27, 388-394.	0.8	19
95	Similar Treatment Outcomes for Radical Cystectomy and Radical Radiotherapy in Invasive Bladder Cancer Treated at a United Kingdom Specialist Treatment Center: In Regard to Kotwal et al. ( <i>Int J Radiat Oncol Biol Phys</i> ) 71, 1601-1602.	0.4	1
96	Contribution of a Single Repeat PSA Test to Prostate Cancer Risk Assessment: Experience from the ProtecT Study. <i>European Urology</i> , 2008, 53, 777-784.	0.9	19
97	Decellularization and sterilization of porcine urinary bladder matrix for tissue engineering in the lower urinary tract. <i>Regenerative Medicine</i> , 2008, 3, 145-156.	0.8	134
98	Durability and Cost-Effectiveness of Transurethral Needle Ablation of the Prostate as an Alternative to Transurethral Resection of the Prostate When $\alpha$ -Adrenergic Antagonist Therapy Fails. <i>Journal of Urology</i> , 2007, 177, 1047-1051.	0.2	29
99	Multifocal Urothelial Cancers With the Mutator Phenotype are of Monoclonal Origin and Require Panurothelial Treatment for Tumor Clearance. <i>Journal of Urology</i> , 2006, 175, 2323-2330.	0.2	58
100	Towards a better understanding of involuntary detrusor activity. <i>BJU International</i> , 2005, 95, 799-803.	1.3	14
101	Transient femoral nerve palsy complicating preoperative ilioinguinal nerve blockade for inguinal herniorrhaphy. <i>British Journal of Surgery</i> , 2005, 81, 897-897.	0.1	40
102	The Road to Cystectomy: Who, When and Why?. <i>EAU Update Series</i> , 2005, 3, 118-128.	0.5	8
103	Investigation of neurokinin-2 and -3 receptors in the human and pig bladder. <i>BJU International</i> , 2003, 92, 787-792.	1.3	18
104	Evaluating ambulatory urodynamics: a prospective study in asymptomatic women. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2003, 110, 83-84.	1.1	3
105	Review of current practice to establish success after vasectomy. <i>British Journal of Surgery</i> , 2002, 88, 290-293.	0.1	20
106	CONVENTIONAL AND AMBULATORY URODYNAMIC FINDINGS IN WOMEN WITH SYMPTOMS SUGGESTIVE OF BLADDER OVERACTIVITY. <i>Journal of Urology</i> , 2001, 166, 2253-2258.	0.2	109
107	A comparison of ambulatory and conventional urodynamic studies in men with borderline outlet obstruction. <i>BJU International</i> , 2001, 83, 400-409.	1.3	33
108	CONVENTIONAL AND AMBULATORY URODYNAMIC FINDINGS IN WOMEN WITH SYMPTOMS SUGGESTIVE OF BLADDER OVERACTIVITY. <i>Journal of Urology</i> , 2001, , 2253-2258.	0.2	4

#	ARTICLE	IF	CITATIONS
109	Standardisation of ambulatory urodynamic monitoring: Report of the Standardisation Sub-committee of the International Continence Society for Ambulatory Urodynamic Studies. <i>Neurourology and Urodynamics</i> , 2000, 19, 113-125.	0.8	123
110	The changing pattern of mortality and morbidity from radical cystectomy. <i>BJU International</i> , 2000, 85, 427-430.	1.3	147
111	The pressure-flow plot in the evaluation of female incontinence. <i>BJU International</i> , 2000, 86, 563-564.	1.3	0
112	URODYNAMIC ASSESSMENT OF THE BASHFUL BLADDER. <i>Journal of Urology</i> , 2000, 163, 215-220.	0.2	19
113	Renal infarction following spontaneous renal vein thrombosis in the puerperium. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 1999, 106, 1223-1224.	1.1	4
114	Pharmacodynamics of anticholinergic agents measured by ambulatory urodynamic monitoring: A study of methodology. <i>Neurourology and Urodynamics</i> , 1999, 18, 223-234.	0.8	23
115	The value of prostate specific antigen (PSA) density and free: total PSA ratio in selecting patients with a normal digital rectal examination and intermediate total PSA levels for further investigation. <i>British Journal of Urology</i> , 1998, 82, 393-397.	0.1	11
116	Painful bone metastases in hormone refractory prostate cancer: economic costs of Strontium-89 and/or external radiotherapy. <i>Current Opinion in Urology</i> , 1998, 8, 336-337.	0.9	0
117	Mechanism of femoral nerve palsy complicating percutaneous ilioinguinal field block.. <i>British Journal of Anaesthesia</i> , 1997, 78, 314-316.	1.5	103
118	Bladder, testicular neoplasm. <i>Current Opinion in Urology</i> , 1997, 7, U19-U20.	0.9	0
119	Safety and efficacy of transurethral needle ablation of the prostate for symptomatic outlet obstruction. <i>BJU International</i> , 1997, 80, 579-586.	1.3	46
120	The Treatment of Vesicovaginal Fistulae. <i>European Urology</i> , 1996, 29, 1-9.	0.9	44
121	A prospective audit of the use of a prostate clinic. <i>BJU International</i> , 1996, 78, 733-736.	1.3	15
122	A simple technique for the intra-operative placement of a suprapubic catheter. <i>British Journal of Urology</i> , 1996, 77, 153-154.	0.1	1
123	Digitally-guided prostatic biopsies - the Sheffield biopsy guide. <i>British Journal of Urology</i> , 1996, 77, 152-152.	0.1	1
124	Fistulae and gynaecological injury to the urinary tract. <i>Current Opinion in Urology</i> , 1995, 5, 191-194.	0.9	1
125	The importance of accurate assessment and conservative management of the open bladder neck in patients with post-pelvic fracture membranous urethral distraction defects. <i>British Journal of Urology</i> , 1995, 75, 65-67.	0.1	30
126	Stone formation on permanent suture material used previously in colposuspension. <i>British Journal of Urology</i> , 1995, 76, 139-140.	0.1	16



#	ARTICLE	IF	CITATIONS
127	Effects of Intravenous Thyrotropin- Releasing Hormone on Urethral Closure Pressure in Females with Voiding Dysfunction. <i>European Urology</i> , 1995, 28, 64-67.	0.9	4
128	Adrenoceptor-mediated contractile responses of the human vas deferens. <i>British Journal of Pharmacology</i> , 1995, 116, 1605-1610.	2.7	42
129	Neural stimulation in the management of the neuropathic bladder. <i>Current Opinion in Urology</i> , 1994, 4, 197-200.	0.9	0
130	Exercise interventions for men with prostate cancer. <i>The Cochrane Library</i> , 0, , .	1.5	2